|
Fig. 3
TBK1/IKKε inhibitors promote β-cell replication. (A–D) Confocal images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 48 hpa, concurrently treated with EdU and DMSO (A), BX795 (B), amlexanox (C), or PIAA (D), respectively, from 0–48 hpa. The number of β-cells that incorporated EdU (white arrows) was substantially increased in TBK1/IKKε-I-treated recovering larvae (B–D) compared to DMSO-treated larvae (A). (E) Quantification of the number (mean ± SD) of total regenerated β-cells (green) and regenerated β-cells that incorporated EdU (yellow) at 48 hpa (in A-D; 5.0 ± 1.3 total regenerated β-cells, of which 0.7 ± 0.5 (DMSO), 11.0 ± 3.4, of which 4.6 ± 1.8 (BX795), 12.8 ± 4.8, of which 5.2 ± 2.8 (amlexanox), and 20.6 ± 3.1, of which 11.0 ± 1.9 (PIAA) incorporated EdU). (F) The percentage (mean ± SD) of regenerated β-cells that incorporated EdU at 48 hpa (in A-D; 13.0 ± 11.0% (DMSO), 42.0 ± 5.0% (BX795), 39.0 ± 7.0% (amlexanox), and 55.0 ± 14.0% (PIAA)). Cells in 20 planes of confocal images from 10 individual larvae were counted per condition. **P < 0.01; ***P < 0.001.